Exhilarin
On sale on the US market (according to the DSLD)
Metagenics, food supplement from the US market
Exhilarin (Metagenics), a food supplement au code-barres 755571800008, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Metagenics
- Barcode
- 755571800008
- Form
- Tablet
- One serving
- 2 tablets
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Microcrystalline Cellulose, Cellulose, Croscarmellose Sodium, Stearic Acid, Silica, Hypromellose, Medium Chain Triglyceride, Hydroxypropylcellulose
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Total Carbohydrate | Carbohydrate | not stated |
| Dietary Fiber | Fibre | not stated |
| A Proprietary Blend of Herbal Extracts | Blend | 1.2 Gram(s) |
| Holy Basil Leaf Extract | Plant | not stated |
| Ashwagandha Root Extract (Withania somnifera) | Plant | not stated |
| Amla Extract (Phyllanthus emblica) | Plant | not stated |
| Bacopa Whole Plant Extract (Bacopa monnieri) | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Exhilarin
Entered into DSLD on 24 March 2020. Withdrawn from the US market on 7 September 2022 (according to the DSLD).- Active ingredient added : Amla (Emblica officinalis) fruit 5:1 extract (quantity not stated)
- Active ingredient added : Ashwagandha (Withania somnifera) root 15:1 extract (quantity not stated)
- Active ingredient added : Bacopa (Bacopa monnieri) whole plant 8:1 extract (quantity not stated)
- Active ingredient added : Holy Basil (Ocimum sanctum) leaf 8:1 extract (quantity not stated)
- Active ingredient removed : Amla Extract (quantity not stated)
- Active ingredient removed : Ashwagandha Root Extract (quantity not stated)
- Active ingredient removed : Bacopa Whole Plant Extract (quantity not stated)
- Active ingredient removed : Holy Basil Leaf Extract (quantity not stated)
- Same quantity, different name: Total Carbohydrates in this version; Total Carbohydrate on the displayed label (< 1 Gram(s))
Official label: Exhilarin
Entered into DSLD on 25 January 2020. Withdrawn from the US market on 23 February 2024 (according to the DSLD).- Active ingredient added : Amla (Emblica officinalis) fruit 5:1 extract (quantity not stated)
- Active ingredient added : Ashwagandha (Withania somnifera) root 15:1 extract (quantity not stated)
- Active ingredient added : Bacopa (Bacopa monnieri) whole plant 8:1 extract (quantity not stated)
- Active ingredient added : Holy Basil (Ocimum sanctum) leaf 8:1 extract (quantity not stated)
- Active ingredient removed : Amla Extract (quantity not stated)
- Active ingredient removed : Ashwagandha Root Extract (quantity not stated)
- Active ingredient removed : Bacopa Whole Plant Extract (quantity not stated)
- Active ingredient removed : Dietary Fiber (< 1 Gram(s))
- Active ingredient removed : Holy Basil Leaf Extract (quantity not stated)
- Active ingredient removed : Total Carbohydrate (< 1 Gram(s))
Official label: Exhilarin
Entered into DSLD on 25 October 2013. Withdrawn from the US market on 3 July 2019 (according to the DSLD).- Active ingredient added : Amla Fruit 3:1 (quantity not stated)
- Active ingredient added : Ashwagandha Root 15:1 Extract (quantity not stated)
- Active ingredient added : Bacopa Leaf 4:1 Extract (quantity not stated)
- Active ingredient added : Holy Basil Leaf 10:1 Extract (quantity not stated)
- Active ingredient removed : Amla Extract (quantity not stated)
- Active ingredient removed : Ashwagandha Root Extract (quantity not stated)
- Active ingredient removed : Bacopa Whole Plant Extract (quantity not stated)
- Active ingredient removed : Dietary Fiber (< 1 Gram(s))
- Active ingredient removed : Holy Basil Leaf Extract (quantity not stated)
- Active ingredient removed : Total Carbohydrate (< 1 Gram(s))
- Different unit, without conversion : A Proprietary Blend of Herbal Extracts: 1,230 mg in this version; 1.2 Gram(s) on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ashwagandha Root Extract
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Sources cited by Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Amla Extract
Read the warning, when it applies and the studies cited
Amla - Phyllanthus Emblica
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Applies to products providing more than 3 grams of amla, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Condition of application: Amlapitta, Digestive tonic.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Laxative.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).
Sources cited by Health Canada (3)
- CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
- Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.
Contraindications
Condition of application: Laxative.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Known adverse reactions
Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.
When using this product you may experience a laxative effect.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Metagenics
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Exhilarin (Metagenics): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/755571800008-exhilarin-metagenics, updated 23 August 2023.